Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

24-10-2017 | Acute myeloid leukemia | Article

Measurement of Residual Disease in Acute Myeloid Leukemia

Journal: Current Hematologic Malignancy Reports

Authors: Rahul S. Vedula, R. Coleman Lindsley

Publisher: Springer US

Login to get access

Abstract

Purpose of Review

Assessment of measurable residual disease (MRD) after treatment can identify patients with acute myeloid leukemia (AML) that are at high risk of poor outcomes. However, there is no consensus yet regarding a standardized approach to measuring MRD that is most clinically meaningful. We review multiparameter flow cytometry (MFC) and reverse transcriptase polymerase chain reaction (RT-PCR), and discuss a framework for assessing remission MRD using next-generation sequencing (NGS).

Recent Findings

MFC and RT-PCR may not fully capitalize on the major advances that have been made in characterizing the genetic landscape of AML, which has offered insight into the biological and clinical implications of clonal genetic architecture. NGS has increasingly been shown to provide a qualitative and quantitative assessment of MRD with significant prognostic implications.

Summary

The assessment of clonal architecture by NGS may complement or extend existing approaches for MRD monitoring. Long-term serial monitoring of diagnostic, remission, and relapse samples with clinical correlation will need to be performed in order to determine the impact of various MRD patterns using this technique.
Literature
1.
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.
2.
Dick JE. Tumor archaeology: tracking leukemic evolution to its origins. Sci Transl Med. 2014;6:238fs23.CrossRefPubMed
3.
Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.CrossRefPubMedPubMedCentral
4.
•• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264–78. Important study demonstrating the acquisition of mutations in a stereotypical fashion as a basis for clonal evolution. CrossRefPubMedPubMedCentral
5.
Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118.CrossRefPubMedPubMedCentral
6.
Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci. 2014;111:2548–53.CrossRefPubMedPubMedCentral
7.
•• Sperling AS, Gibson CJ, Ebert BL (2017) The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17:5–19. Review of spectrum of mutations by class in myeloid neoplasm.
8.
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9 LP-16.
9.
Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.CrossRefPubMedPubMedCentral
10.
Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547:104–8.CrossRefPubMed
11.
• Lindsley RC, Mar BG, Mazzola E, et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367 LP-1376. Study demonstrating the association of certain classes of somatic mutations that provide the genetic basis of distinct pathways of AML development.
12.
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.CrossRefPubMedPubMedCentral
13.
Papaemmanuil E, Gerstung M, Malcovati L, et al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616 LP-3627.
14.
Grimwade D, Hills RK, Moorman A V, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354 LP-365.
15.
Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:497–529.CrossRefPubMed
16.
Döhner H, Estey E, Grimwade D, et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424 LP-447.
17.
Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–89.CrossRefPubMedPubMedCentral
18.
Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52:363–71.CrossRefPubMed
19.
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH (2006) Age and acute myeloid leukemia. Blood 107:3481 LP-3485.
20.
Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2006;106:1090–8.CrossRefPubMed
21.
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–24.CrossRefPubMedPubMedCentral
22.
Stone RM, Mazzola E, Neuberg D, et al. Phase III open-label randomized study of Cytarabine in combination with Amonafide L-malate or Daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015;33:1252–7.CrossRefPubMed
23.
Grossmann V, Schnittger S, Kohlmann A, et al (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120:2963 LP-2972.
24.
Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology group, Southwest Oncology group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010;28:1766–71.CrossRefPubMedPubMedCentral
25.
Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30:3625–32.CrossRefPubMedPubMedCentral
26.
Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci G, Lo Coco F (1993) Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 82:3556 LP-3559.
27.
Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukemia. Nat Rev Clin Oncol. 2013;10:460–71.CrossRefPubMedPubMedCentral
28.
Loken MR, Alonzo TA, Pardo L, et al (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood 120:1581 LP-1588.
29.
Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258–64.CrossRefPubMed
30.
Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A Study. J Clin Oncol. 2013;31:3889–97.CrossRefPubMed
31.
Walter RB, Buckley SA, Pagel JM, et al (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122:1813 LP-1821.
32.
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.CrossRefPubMed
33.
Feller N, van der Velden VHJ, Brooimans RA, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J. 2013;3:e129.CrossRefPubMedPubMedCentral
34.
Baer MR, Stewart CC, Dodge RK, et al (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (cancer and leukemia group B study 8361). Blood 97:3574 LP-3580.
35.
Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol. 2011;153:421–36.CrossRefPubMed
36.
Hokland P, Ommen HB (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 117:2577 LP-2584.
37.
Grimwade D, Freeman SD (2014) Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood 124:3345 LP-3355.
38.
Yin JAL, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120:2826 LP-2835.
39.
Jourdan E, Boissel N, Chevret S, et al (2013) Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121:2213 LP-2223.
40.
Zhu H-H, Zhang X-H, Qin Y-Z, et al (2013) MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 121:4056 LP-4062.
41.
Krönke J, Schlenk RF, Jensen K-O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol. 2011;29:2709–16.CrossRefPubMed
42.
• Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016;375:e9. Landmark study of the use of NPM1 RT-PCR for MRD.
43.
Guolo F, Minetto P, Clavio M, et al. Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. Haematologica. 2017.
44.
Candoni A, De Marchi F, Zanini F, et al. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Exp Hematol. 2017;49:25–33.CrossRefPubMed
45.
Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.CrossRefPubMedPubMedCentral
46.
Kuo FC, Mar BG, Lindsley RC, Lindeman NI. The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood. 2017.
47.
Duncavage EJ, Tandon B. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes. Int J Lab Hematol. 2015;37:115–21.CrossRefPubMed
48.
•• Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090–8. Quantitatively and qualitatively described the genetic architecture of secondary AML from MDS to transformation. CrossRefPubMedPubMedCentral
49.
Jacobson RJ, Temple MJ, Singer JW, Raskind W, Powell J, Fialkow PJ. A clonal complete remission in a patient with acute nonlymphocytic leukemia originating in a multipotent stem cell. N Engl J Med. 1984;310:1513–7.CrossRefPubMed
50.
Gale RE, Wheadon H, Goldstone AH, Linch DC, Burnett AK. Frequency of clonal remission in acute myeloid leukaemia. Lancet. 1993;341:138–42.CrossRefPubMed
51.
Nucifora G, Larson RA, Rowley JD (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712 LP-715.
52.
• Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314:811–22. NGS of AML samples at diagnosis, remission, and relapse demonstrating significance of mutation clearance. CrossRefPubMedPubMedCentral
53.
Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia French association. Oncotarget. 2015;6:42345–53.CrossRefPubMedPubMedCentral
54.
• Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol. 2014;167:478–86. Description of DNMT3A clonal remission. CrossRefPubMed
55.
Gaidzik VI, Weber D, Paschka P, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2017
56.
Bhatnagar B, Eisfeld A-K, Nicolet D, et al. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol. 2016;175:226–36.CrossRefPubMedPubMedCentral
57.
Thol F, Kölking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosom Cancer. 2012;51:689–95.CrossRefPubMed
58.
• Parkin B, Londoño-joshi A, Kang Q, Tewari M, Rhim AD, Malek SN. Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. J Clin Invest. 2017;127:1–12. Droplet-digital PCR of AML samples at diagnosis, remission, and relapse with ultrasensitive detection of mutations for MRD. CrossRef
59.
Shlush LI, Zandi S, Mitchell A, et al (2014) Identification of preleukaemic haematopoietic stem cells in acute leukaemia. Nature 506:328–333.
60.
Amatangelo MD, Quek L, Shih A, et al (2017) Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood.
61.
Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. 687 Measurable residual disease testing in acute myeloid leukaemia. 688 Leukemia. 2017;31:1482–90.